rosiglitazone has been researched along with Neoplasms in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 18 (62.07) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Appay, V; Boddaert, J; Cabral-Piccin, MP; Caputo, A; Clave, E; Dubois, M; Dupré, L; Folcher, V; Frere, JJ; Fusaro, M; Gallerani, E; Gavioli, R; Gostick, E; Llewellyn-Lacey, S; Nicoli, F; Papagno, L; Price, DA; Toubert, A; Vallet, H | 1 |
| Kaminskyy, D; Khyluk, D; Kryshchyshyn-Dylevych, A; Lesyk, R; Skóra, B; Szychowski, KA | 1 |
| Gao, M; He, F; He, J; Huang, Y; Li, B; Li, X; Lian, J; Shi, C; Zeng, Y | 1 |
| Dang, YF; Gong, FL; Guo, XL; Jiang, XN | 1 |
| Chen, SZ; Xiao, JD | 1 |
| Chevalier, S; Farsijani, S | 1 |
| Anker, SD; Doehner, W; Lainscak, M; Palus, S; Springer, J; Trobec, K; Tschirner, A; von Haehling, S | 1 |
| Curtis, PS; Home, PD; Jones, NP | 1 |
| Azimi, A | 1 |
| Baggstrom, MQ; Fracasso, PM; Govindan, R; Read, WL | 1 |
| Cheong, SJ; Jeong, HJ; Kim, DW; Kim, EM; Kim, SL; Lee, CM; Lim, ST; Sohn, MH; Yim, CY | 1 |
| Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ | 1 |
| Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC | 1 |
| Beck-Nielsen, H; Home, PD; Jones, NP; Kahn, SE; Noronha, D; Viberti, G | 1 |
| Drazen, JM; Wood, AJ | 1 |
| Bowker, SL; Johnson, JA | 1 |
| Frazier, SA; Guerrero, TA; McKemie, DS; Rodriguez, CO; Skorupski, KA | 1 |
| Afzal, R; Bosch, J; Dagenais, G; Diaz, R; Gerstein, H; Holman, R; Probstfield, J; Punthakee, Z; Ramachandran, A; Riddle, M; Rydén, LE; Yusuf, S; Zinman, B | 1 |
| Asp, ML; Belury, MA; Kliewer, KL; Tian, M | 1 |
| Allstadt Frazier, S; Guerrero, TA; Kass, PH; LaChapelle, H; McKemie, DS; Rodriguez, CO; Skorupski, KA | 1 |
| Colburn, D; Colevas, AD; Graham, RA; LoRusso, PM; Low, JA; Malhi, V; Mita, M; Piha-Paul, SA; Yin, M | 1 |
| Ravid, M | 1 |
| Auwerx, J; Egler, V; Fajas, L; Lefebvre, AM; Miard, S; Reiter, R | 1 |
| Horinaka, M; Kouhara, J; Nakata, S; Sakai, T; Shiraishi, T; Wakada, M; Yoshida, T | 1 |
| Littenberg, B; MacLean, CD; Ramos-Nino, ME | 1 |
| Lamanna, C; Mannucci, E; Marchionni, N; Monami, M | 1 |
| Wood, I | 1 |
7 review(s) available for rosiglitazone and Neoplasms
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Clinical Trials, Phase II as Topic; Humans; Neoplasms; PPAR gamma; Rosiglitazone | 2018 |
Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment.
Topics: Adipose Tissue; Animals; Cachexia; Diabetes Mellitus, Type 2; Energy Metabolism; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Muscular Atrophy; Neoplasms; Nutritional Support; Proteins; Rosiglitazone; Thiazolidinediones | 2014 |
Hypothesis: ROBOPHERA, a phosphatase and tensin homolog-targeted antineoplastic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Differentiation; Chemoradiotherapy; Drug Synergism; Ethanol; Humans; Molecular Targeted Therapy; Neoplasms; Neoplastic Stem Cells; Phosphatidylserines; PTEN Phosphohydrolase; Rosiglitazone; Thiazolidinediones | 2017 |
Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Neoplasms; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2011 |
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Middle Aged; Neoplasms; Patient Selection; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2008 |
7 trial(s) available for rosiglitazone and Neoplasms
| Article | Year |
|---|---|
Cancer and bone fractures in observational follow-up of the RECORD study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoplasms; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2015 |
A phase I study of bexarotene and rosiglitazone in patients with refractory cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Female; Humans; Male; Middle Aged; Neoplasms; Rosiglitazone; Tetrahydronaphthalenes; Thiazolidinediones | 2008 |
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Topics: Administration, Oral; Angina, Unstable; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Drug Utilization; Female; Fractures, Bone; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Neoplasms; Prospective Studies; Rosiglitazone; Sex Factors; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Thiazolidines; Treatment Outcome | 2010 |
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholecalciferol; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Early Termination of Clinical Trials; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Neoplasms; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2012 |
Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Female; Hypoglycemic Agents; Injections, Intravenous; Male; Neoplasms; Rosiglitazone; Thiazolidinediones | 2014 |
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
Topics: Aged; Anilides; Antineoplastic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cohort Studies; Contraceptives, Oral, Combined; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Drug Interactions; Ethinyl Estradiol; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Norethindrone; Pyridines; Rosiglitazone; Thiazolidinediones | 2013 |
15 other study(ies) available for rosiglitazone and Neoplasms
| Article | Year |
|---|---|
Altered Basal Lipid Metabolism Underlies the Functional Impairment of Naive CD8
Topics: Adult; Aged; Aged, 80 and over; Aging; Apoptosis; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Division; COVID-19; Female; Fenofibrate; Glucose; HLA-A2 Antigen; Humans; Hypolipidemic Agents; Immunocompetence; Influenza, Human; Lipid Metabolism; Lymphocyte Activation; Male; MART-1 Antigen; Middle Aged; Neoplasms; Peptide Fragments; Rosiglitazone; Single-Blind Method; Vaccination; Viral Vaccines; Young Adult | 2022 |
4-thiazolidinone-based derivatives rosiglitazone and pioglitazone affect the expression of antioxidant enzymes in different human cell lines.
Topics: A549 Cells; Antioxidants; Apoptosis; Caco-2 Cells; Caspase 3; Cell Line; Cell Line, Tumor; Humans; Neoplasms; Oxidative Stress; Pioglitazone; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Thiazolidines | 2021 |
The PPARγ agonist rosiglitazone sensitizes the BH3 mimetic (-)-gossypol to induce apoptosis in cancer cells with high level of Bcl-2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gossypol; Humans; Male; MAP Kinase Kinase 4; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Rosiglitazone | 2018 |
Rosiglitazone and imidapril alone or in combination alleviate muscle and adipose depletion in a murine cancer cachexia model.
Topics: Adipose Tissue; Animals; Biomarkers; Body Weight; Cachexia; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Imidazolidines; Inflammation Mediators; Insulin; Male; Mice; Muscle Proteins; Muscles; Muscular Atrophy; Neoplasms; Organ Size; Rosiglitazone; SKP Cullin F-Box Protein Ligases; Thiazolidinediones; Tripartite Motif Proteins; Tumor Burden; Ubiquitin-Protein Ligases | 2014 |
Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia.
Topics: Adipose Tissue; Animals; Body Composition; Body Fluid Compartments; Cachexia; Cardiac Output; Disease Models, Animal; Heart; Hypoglycemic Agents; Male; Muscle, Skeletal; Neoplasms; Random Allocation; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Ventricular Function, Left; Weight Loss | 2014 |
The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells.
Topics: Animals; Biological Transport; Cell Line, Tumor; Dimethyl Sulfoxide; Fluorodeoxyglucose F18; Gene Expression Regulation; Glucose; Glucose Transport Proteins, Facilitative; Hexokinase; Humans; Inflammation; Macrophages; Mice; Neoplasms; Positron-Emission Tomography; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed | 2009 |
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Pancreatic Neoplasms; Rosiglitazone; Thiazolidinediones | 2011 |
Don't mess with the DSMB.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hypoglycemic Agents; Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones; United States | 2010 |
Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Carboplatin; Chromatography, High Pressure Liquid; Dog Diseases; Dogs; Female; Half-Life; Male; Neoplasms; Rosiglitazone; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazolidinediones | 2011 |
Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia.
Topics: Adipose Tissue; Animals; Anorexia; Blood Glucose; Cachexia; Eating; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Mice; Muscle Strength; Neoplasms; Organ Size; Proteolysis; Rosiglitazone; Thiazolidinediones; Weight Loss | 2011 |
Carcinophobia in clinical research.
Topics: Angiotensin Receptor Antagonists; Animals; Biomedical Research; Causality; Clopidogrel; Cyclooxygenase 2 Inhibitors; Humans; Incidence; Insulin Glargine; Insulin, Long-Acting; Neoplasms; Rosiglitazone; Thiazolidinediones; Ticlopidine | 2012 |
PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner.
Topics: 3T3 Cells; Adipocytes; Animals; Apoptosis; Blotting, Northern; Blotting, Western; Bromodeoxyuridine; Cell Cycle; Cell Division; Cell Nucleus; Flow Cytometry; G1 Phase; G2 Phase; Gene Expression Regulation; Histone Deacetylases; In Situ Nick-End Labeling; Luciferases; Mice; Microscopy, Fluorescence; Mitosis; Neoplasms; Plasmids; Precipitin Tests; Receptors, Cytoplasmic and Nuclear; Retinoblastoma Protein; RNA, Small Interfering; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection | 2003 |
15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Gene Expression; Humans; Jurkat Cells; Membrane Glycoproteins; Neoplasms; Pioglitazone; PPAR gamma; Prostaglandin D2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA Stability; RNA, Messenger; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2006 |
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System.
Topics: Age Distribution; Causality; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; New Hampshire; New York; Pioglitazone; Prevalence; Rosiglitazone; Sex Distribution; Thiazolidinediones; Vermont | 2007 |
How can anti-diabetics suppress tumours?
Topics: Humans; Hypoglycemic Agents; Neoplasms; Phosphoric Monoester Hydrolases; PTEN Phosphohydrolase; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Suppressor Proteins | 2001 |